Alan Kliger
Nephrology · New Haven, CTNPI 1619963923
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Fresenius USA Marketing, Inc. accounts for 66.7% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2020 at $2,840 and has fallen 98.3% since, to $48 in 2024.
Across 82 payments — averaging $56.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$3K
- AstraZeneca$356
- Vifor Pharma, Inc.$150
- Bayer$146
- Amgen$111
- Mallinckrodt Hospital Products Inc.$96
- plus $674 from 13 others
What the payments were for
- Speaking & faculty fees$99922%
- Travel & lodging$84218%
- Food & beverage$2,25649%
- Education$351%
- Gifts$47510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 11 | $3,075 |
| AstraZeneca(2 entities) | 15 | $356 |
| Vifor Pharma, Inc. | 6 | $150 |
| Bayer | 7 | $146 |
| Amgen(2 entities) | 5 | $111 |
| Mallinckrodt Hospital Products Inc. | 3 | $96 |
| ANI Pharmaceuticals, Inc. | 3 | $77 |
| Xeris Pharmaceuticals, Inc. | 4 | $71 |
| Akebia Therapeutics Inc | 3 | $71 |
| GSK | 4 | $64 |
| Travere Therapeutics, Inc. | 3 | $59 |
| Genentech USA, Inc. | 4 | $58 |
| Aurinia Pharma U.S., Inc. | 2 | $55 |
| Otsuka America Pharmaceutical, Inc. | 3 | $52 |
| Novartis | 3 | $51 |
| Sanofi | 2 | $42 |
| Calliditas Therapeutics US Inc. | 2 | $34 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Johnson & Johnson | 1 | $12 |
How this compares
$4,608 in reported general payments places this provider in the 80th percentile of 144 nephrology providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 22 | $28,757 |
| Allopurinol | 11 | $53 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $356 | $28,75722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 144 nephrology providers in Connecticut.
Other nephrology in New Haven
- Robert AlpernNew Haven$4.9M
- Richard FormicaNew Haven$198K
- Stefan SomloNew Haven$111K
- Fredric FinkelsteinNew Haven$70K
- Justin BelcherNew Haven$59K
- Ladan GolestanehNew Haven$54K
- Aldo PeixotoNew Haven$17K
- Ali Abu-AlfaNew Haven$16K
- Lloyd CantleyNew Haven$14K
- Sue ChangNew Haven$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.